Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression. Some authors have suggested that it may mainly occur late in the disease course or even be a marker for involuting nephrogenic systemic fibrosis. Here, we present a 27-year-old woman with a 7-year history of nephrogenic systemic fibrosis, who developed cutaneous osseous metaplasia.
Berk
David R
DR
Department of Internal Medicine, Division of Dermatology, Washington University School of Medicine, St. Louis, Missouri, USA. dberk@dom.wustl.edu
Miller
Alicia
A
Scarlett
Debra
D
Wippold
Franz J
FJ
Bayliss
Susan J
SJ
Lu
Dongsi
D
D000328:Adult; D000700:Analgesics / Q000009:adverse effects; D002114:Calcinosis / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000473:pathology*; D016030:Kidney Transplantation; D008180:Lupus Erythematosus, Systemic / Q000473:pathology; D008679:Metaplasia / Q000473:pathology; D054989:Nephrogenic Fibrosing Dermopathy / Q000188:drug therapy / Q000473:pathology*; D000069583:Pregabalin; D011796:Quinacrine / Q000627:therapeutic use; D012867:Skin / Q000473:pathology*; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives
D000700:Analgesics; D006886:Hydroxychloroquine; D013792:Thalidomide; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D011796:Quinacrine